Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Account Payables
Amounts the company owes suppliers for goods and services received.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 56.9% from a year ago
Account payables stood at $4.7M at the end of Q1 FY2026, up 56.9% from a year earlier and down 25.2% from the prior quarter. Over 3 fiscal years it compounded at +29.2% a year.
Context
- Account payables amounted to 18.5% of total assets at the end of Q1 FY2026, up 8.6 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +56.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 6.27M USD
- Year-over-year change
- +151.2%
- 4-year CAGR
- +56.1%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.27M | +151.2% |
| FY2024 | 2024-12-31 | 2.5M | -9.9% |
| FY2023 | 2023-12-31 | 2.77M | -4.8% |
| FY2022 | 2022-12-31 | 2.91M | +175.0% |
| FY2021 | 2021-12-31 | 1.06M | — |
Account Payables vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 account payables of $4.7M is the 6th highest of the 11 companies compared; the peer median is $4.51M.
- Its year-over-year change of +56.9% is the 2nd highest of 11, against a peer median of -4.9%.
- Account payables amounts to 18.5% of total assets for NVCT, versus a peer median of 1.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.45B | +110780.3% | -21.2% | 0.7% | |
| Jun 2026 | $12.09M | -46.1% | +64.3% | 1.6% | |
| Mar 2026 | $10.84M | +7.9% | +56.2% | 2.3% | |
| Mar 2026 | $9.6M | +33.4% | +36.4% | 4.2% | |
| Mar 2026 | $4.73M | -17.6% | +236.3% | 4.9% | |
| Mar 2026 | $4.7M | +56.9% | +29.2% | 18.5% | |
| Mar 2026 | $4.29M | -35.2% | -0.8% | 2.0% | |
| Mar 2026 | $3.38M | +43.6% | +32.0% | 0.3% | |
| Mar 2026 | $3.23M | +10.3% | -27.5% | 7.9% | |
| Mar 2026 | $2.9M | -43.9% | +42.6% | 0.7% | |
| Mar 2026 | $906K | -42.5% | -22.3% | 0.4% | |
| Peer median (excluding NVCT) | $4.51M | -4.9% | +34.2% | 1.8% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.